Abivax S.A.(us:ABVX)

    7.07

    -7.58%

    Updated on 2024-12-23

    Open:7.60
    Close:7.07
    High:7.63
    Low:7.00
    Pre Close:7.65
    Volume:350604.00
    Amount:2.55M
    Turnover:0.56%
    Shares:62.92M
    MarketCap:444.85M

    About Abivax S.A. Company

    Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.

    Company Name: Abivax S.A.
    Company Address: 7-11 Boulevard Haussmann
    Employees: 61
    Fiscar Year: 12-31
    IPO Date:
    CIK: 1956827

    View all SEC Filings

    About

    Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.
    Address:7-11 Boulevard Haussmann

    Market Movers